Travere Therapeutics, Inc. (NASDAQ:TVTX) Position Boosted by Barclays PLC

Barclays PLC lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 135.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 396,570 shares of the company's stock after acquiring an additional 227,802 shares during the period. Barclays PLC owned 0.51% of Travere Therapeutics worth $6,908,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sterling Capital Management LLC grew its position in Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock valued at $41,000 after buying an additional 2,115 shares during the last quarter. R Squared Ltd purchased a new position in Travere Therapeutics during the 4th quarter worth $53,000. Summit Investment Advisors Inc. raised its position in Travere Therapeutics by 9.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after buying an additional 667 shares during the last quarter. Victory Capital Management Inc. purchased a new position in Travere Therapeutics during the 4th quarter worth $182,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in Travere Therapeutics during the 4th quarter worth $192,000.

Insider Buying and Selling

In other Travere Therapeutics news, CFO Christopher R. Cline sold 5,192 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total transaction of $104,463.04. Following the completion of the sale, the chief financial officer now directly owns 90,038 shares in the company, valued at $1,811,564.56. The trade was a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric M. Dube sold 11,375 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total transaction of $273,455.00. Following the sale, the chief executive officer now owns 419,173 shares of the company's stock, valued at approximately $10,076,918.92. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 156,330 shares of company stock valued at $3,507,377. Insiders own 4.06% of the company's stock.

Travere Therapeutics Trading Up 3.6 %

Shares of Travere Therapeutics stock traded up $0.73 during mid-day trading on Wednesday, hitting $20.81. 1,514,352 shares of the stock were exchanged, compared to its average volume of 1,519,495. Travere Therapeutics, Inc. has a twelve month low of $5.54 and a twelve month high of $25.29. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -5.08 and a beta of 0.84. The company has a 50-day simple moving average of $18.08 and a 200 day simple moving average of $18.69. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Research analysts forecast that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TVTX. Citigroup increased their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a report on Monday, February 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Travere Therapeutics in a report on Wednesday, April 23rd. Guggenheim reiterated a "buy" rating and issued a $47.00 price target on shares of Travere Therapeutics in a report on Monday, April 14th. Bank of America raised their target price on shares of Travere Therapeutics from $29.00 to $31.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Finally, JPMorgan Chase & Co. raised their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $32.08.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.